Medicure Inc V.MPH

Alternate Symbol(s): MCUJF

Healthcare Biotechnology

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.

TSXV:MPH - Post by User

Medicure Inc

Bullboard Posts

Comment by apainteron May 30, 2015 2:24pm

151 Views

Post# 23781071

RE:RE:RE:Excellent results!!!

Hi All,

An excellent positive article about Medicure by an ex employee of the Co.

https://www.cantechletter.com/2015/03/medicure-is-persevering-on-the-prairies/

However, only this paragraph worries me
How much can AGGRASTAT grow? Sales for the GP IIb/IIIa inhibitor class have been steadily declining over the past decade. Integrillin, the leading GP IIb/IIIa inhibitor, will likely be generic mid-2015, putting price pressure on the class. So AGGRASTAT is not without its ongoing challenges. However, with only about 4% market share and increasing hospital adoption, near-term growth for AGGRASTAT seems like a safe bet.

Any comments or insight on this would be appreciated
Thanks

Bullboard Posts

Sirios Resource discovers visible gold in Quebec